New combo aims to zap head & neck cancer without radiation
NCT ID NCT03174275
First seen Feb 26, 2026 · Last updated May 12, 2026 · Updated 11 times
Summary
This study tests a three-drug combination (carboplatin, nab-paclitaxel, and durvalumab) given before surgery to people with advanced head and neck cancer that can be removed. The goal is to shrink or eliminate the tumor so that radiation—which has harsh side effects—may not be needed. About 39 adults with stage III or IV squamous cell carcinoma of the head and neck will take part. The main measure is whether the cancer is completely gone at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.